J. Omar Muñoz-Bello

Dr. J. Omar Muñoz-Bello

Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Tlalpan, Mexico
orcid
associate researcher

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2015 in Viruses
Verified
Journal Article
Open access
PDF file
J. Omar Muñoz-BelloJ. Omar Muñoz-Bello
J. Omar Muñoz-Bello
LNLeslie Olmedo Nieva
Leslie Olmedo Nieva
ACAdriana Contreras
Adriana Contreras
AGAlma Mariana Fuentes Gonzalez
Alma Mariana Fuentes Gonzalez
LRLeticia Rocha-Zavaleta
Leticia Rocha-Zavaleta
MLMarcela Lizano
Marcela Lizano
Cell signaling pathways are the mechanisms by which cells transduce external stimuli, which control the transcription of genes, to regulate diverse biological effects. In cancer, distinct signaling pathways, such as the Wnt/β-catenin pathway, have been implicated in the deregulation of critical molecular processes that affect cell proliferation and differentiation. For example, changes in β-catenin localization have been identified in Human Papillomavirus (HPV)-related cancers as the lesion progresses. Specifically, β-catenin relocates from the membrane/cytoplasm to the nucleus, suggesting that this transcription regulator participates in cervical carcinogenesis. The E6 and E7 oncoproteins are responsible for the transforming activity of HPV, and some studies have implicated these viral oncoproteins in the regulation of the Wnt/β-catenin pathway. Nevertheless, new interactions of HPV oncoproteins with cellular proteins are emerging, and the study of the biological effects of such interactions will help to understand HPV-related carcinogenesis. Viruses 2015, 7 4735 This review addresses the accumulated evidence of the involvement of the HPV E6 and E7 oncoproteins in the activation of the Wnt/β-catenin pathway.

27 September 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
LALízbeth Ayala-Domínguez
Lízbeth Ayala-Domínguez
LOLeslie Olmedo-Nieva
Leslie Olmedo-Nieva
J. Omar Muñoz-BelloJ. Omar Muñoz-Bello
J. Omar Muñoz-Bello
ACAdriana Contreras-Paredes
Adriana Contreras-Paredes
JMJoaquin Manzo-Merino
Joaquin Manzo-Merino
MLMarcela Lizano
Marcela Lizano
Solid tumors carry out the formation of new vessels providing blood supply for growth, tumor maintenance, and metastasis. Several processes take place during tumor vascularization. In angiogenesis, new vessels are derived from endothelial cells of pre-existing vessels; while in vasculogenesis, new vessels are formed de novo from endothelial progenitor cells, creating an abnormal, immature, and disorganized vascular network. Moreover, highly aggressive tumor cells form structures similar to vessels, providing a pathway for perfusion; this process is named vasculogenic mimicry (VM), where vessel-like channels mimic the function of vessels and transport plasma and blood cells. VM is developed by numerous types of aggressive tumors, including ovarian carcinoma which is the second most common cause of death among gynecological cancers. VM has been associated with poor patient outcome and survival in ovarian cancer, although the involved mechanisms are still under investigation. Several signaling molecules have an important role in VM in ovarian cancer, by regulating the expression of genes related to vascular, embryogenic, and hypoxic signaling pathways. In this review, we provide an overview of the current knowledge of the signaling molecules involved in the promotion and regulation of VM in ovarian cancer. The clinical implications and the potential benefit of identification and targeting of VM related molecules for ovarian cancer treatment are also discussed.

20 January 2022 in Cells
Verified
Journal Article
Open access
PDF file
Deisy Segura-VillalobosDeisy Segura-Villalobos
Deisy Segura-Villalobos
IRItzel G. Ramírez-Moreno
Itzel G. Ramírez-Moreno
LALizbeth Magnolia Martinez Aguilar
Lizbeth Magnolia Martinez Aguilar
Alfredo Ibarra-SánchezAlfredo Ibarra-Sánchez
Alfredo Ibarra-Sánchez
J. Omar Muñoz-BelloJ. Omar Muñoz-Bello
J. Omar Muñoz-Bello
CGClaudia González-Espinosa
Claudia González-Espinosa
Mast cells (MCs) are tissue-resident immune cells that are important players in diseases associated with chronic inflammation such as cancer. Since MCs can infiltrate solid tumors and promote or limit tumor growth, a possible polarization of MCs to pro-tumoral or anti-tumoral phenotypes has been proposed and remains as a challenging research field. Here, we review the recent evidence regarding the complex relationship between MCs and tumor cells. In particular, we consider: (1) the multifaceted role of MCs on tumor growth suggested by histological analysis of tumor biopsies and studies performed in MC-deficient animal models; (2) the signaling pathways triggered by tumor-derived chemotactic mediators and bioactive lipids that promote MC migration and modulate their function inside tumors; (3) the possible phenotypic changes on MCs triggered by prevalent conditions in the tumor microenvironment (TME) such as hypoxia; (4) the signaling pathways that specifically lead to the production of angiogenic factors, mainly VEGF; and (5) the possible role of MCs on tumor fibrosis and metastasis. Finally, we discuss the novel literature on the molecular mechanisms potentially related to phenotypic changes that MCs undergo into the TME and some therapeutic strategies targeting MC activation to limit tumor growth.

18 January 2018 in Viruses
Verified
Journal Article
Open access
PDF file
LNLeslie Olmedo Nieva
Leslie Olmedo Nieva
J. Omar Muñoz-BelloJ. Omar Muñoz-Bello
J. Omar Muñoz-Bello
ACAdriana Contreras
Adriana Contreras
MLMarcela Lizano
Marcela Lizano
Persistent infections with High Risk Human Papillomaviruses (HR-HPVs) are the main cause of cervical cancer development. The E6 and E7 oncoproteins of HR-HPVs are derived from a polycistronic pre-mRNA transcribed from an HPV early promoter. Through alternative splicing, this pre-mRNA produces a variety of E6 spliced transcripts termed E6*. In pre-malignant lesions and HPV-related cancers, different E6/E6* transcriptional patterns have been found, although they have not been clearly associated to cancer development. Moreover, there is a controversy about the participation of E6* proteins in cancer progression. This review addresses the regulation of E6 splicing and the different functions that have been found for E6* proteins, as well as their possible role in HPV-induced carcinogenesis.

20 September 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LCLeonardo Josué Castro-Muñoz
Leonardo Josué Castro-Muñoz
JMJoaquin Manzo-Merino
Joaquin Manzo-Merino
J. Omar Muñoz-BelloJ. Omar Muñoz-Bello
J. Omar Muñoz-Bello
LOLeslie Olmedo-Nieva
Leslie Olmedo-Nieva
Alberto Cedro-TandaAlberto Cedro-Tanda
Alberto Cedro-Tanda
MLMarcela Lizano
Marcela Lizano
The Human Papillomavirus (HPV) E1 protein is the only viral protein with enzymatic activity. The main known function of this protein is the regulation of the viral DNA replication. Nevertheless, it has been demonstrated that the ablation of HPV18 E1 mRNA in HeLa cells promotes a deregulation of several genes, particularly those involved in host defense mechanisms against viral infections; however, the specific contribution of E1 protein in HPV-independent context has not been studied. The aim of this work was to determine the effect of the HPV E1 protein in the regulation of cellular gene expression profiles evaluated through RNA-seq. We found that E1 proteins from HPV16 and 18 induced an overexpression of different set of genes associated with proliferation and differentiation processes, as well as downregulation of immune response genes, including IFNβ1 and IFNλ1 and Interferon-stimulated gene (ISG), which are important components involved in the antiviral immune response. Together, our results indicate that HR-(High-Risk) and LR-(Low-Risk) HPV E1 proteins play an important role in inhibiting the anti-viral immune response.

Verified
Journal Article
Open access
PDF file
J. Omar Muñoz-BelloJ. Omar Muñoz-Bello
J. Omar Muñoz-Bello
ACA Carrillo-Garcia
A Carrillo-Garcia
MLMarcela Lizano
Marcela Lizano
Cervical cancer (CC) continues to be a major public health problem in Mexico, ranking second among cancers in women. A persistent infection with human papillomaviruses (HPV) is the main risk factor for CC development. In addition, a significant fraction of other cancers including those of the anus, oropharynx, and penis are also related to HPV infection. In CC, HPV-16 is the most prevalent high-risk HPV type, followed by HPV-18, both being responsible for 70% of cases. HPV intratype variant lineages differ in nucleotide sequences by 1–10%, while sublineages differ by 0.5–1%. Several studies have postulated that the nucleotide changes that occur between HPV intratype variants are reflected in functional differences and in pathogenicity. Moreover, it has been demonstrated that HPV-16 and -18 intratype variants differentially affect molecular processes in infected cells, changing their biological behavior that finally impacts in the clinical outcome of patients. Mexico has participated in providing knowledge on the geographical distribution of intratype variants of the most prevalent HPVs in premalignant lesions of the cervix and cervical cancer, as well as in other HPV-related tumors. In addition, functional studies have been carried out to assess the cellular effects of intratype variations in HPV proteins. This review addresses the state of the art on the epidemiology of HPV-16 and HPV-18 intratype variants in the Mexican population, as well as their association with persistence, precancer and cervical cancer, and functional aspects related to their biological behavior.